JAK2 and glioma: Furthermore, we compared the lethality of BMN673 with that of the other selected candidate inhibitors: a BET inhibitor (JQ1) (Supplementary Figure S2A), a JAK2 inhibitor (AZ960) (Supplementary Figure S2B), and three inhibitors with reported activity against H3K27M-mutant gliomas, namely, EPZ6438 (an EZH2 inhibitor) (Supplementary Figure S3A), sorafenib (a multikinase inhibitor) (Supplementary Figure S3B), and LBH589 (an HDAC inhibitor) (Supplementary Figure S3C).